Alison Todd

Adj/Professor Alison Todd co-founded SpeeDx in 2009 and is its Chief Scientific Officer. She is an elected Fellow of the Australian Academy of Technology and Engineering; and along with Dr Elisa Mokany, was the recipient of academy’s Clunies Ross Innovation Award in 2020 for “discovery, development, and adoption of a technology that has significantly improved societal or industry capabilities”.

Alison is a serial inventor with a portfolio of 18 patent families that comprises over 85 granted patents which protect SpeeDx ‘s IP including PlexZyme and PlexPrime.She is a pioneer in the field of personalised medicine, having pursued a career which has focused on developing and commercialising diagnostic tests for the tailoring and monitoring of therapy for patients with cancer or infectious diseases.

Prior to founding SpeeDx, Alison was a Senior Research Director at Johnson and Johnson Research Pty Limited, Sydney. She spent nearly 20 years within the pharmaceutical industry and was internationally recognised with the Johnson & Johnson Philip B. Hofmann Research Scientist Award for outstanding achievement in R&D.

Alison studied at the University of Sydney, obtaining a BSc (Hons 1st Class) before completing a PhD through the Faculty of Medicine in conjunction with Royal Prince Alfred Hospital. Alison maintains an active involvement within the academic community and is an Adjunct Professor at the University of New South Wales.